SEIKAGAKU CORPORATION Logo

SEIKAGAKU CORPORATION

A research-based pharmaceutical company specializing in glycoscience.

4548 | T

Overview

Corporate Details

ISIN(s):
JP3414000004
LEI:
Country:
Japan
Address:
千代田区丸の内一丁目6番1号

Description

Seikagaku Corporation is a research-based pharmaceutical company specializing in glycoscience. It focuses on the research, development, manufacturing, and marketing of pharmaceuticals and medical devices derived from glycoconjugates, particularly glycosaminoglycans (GAG) such as hyaluronic acid. The company's primary therapeutic area is orthopedics, offering products like joint function improving agents for osteoarthritis. In addition to finished pharmaceuticals and medical devices, Seikagaku also produces and supplies bulk active ingredients and a range of biochemicals, including enzymes and endotoxin-detecting reagents for research and quality control applications.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-12 06:56
確認書
Japanese 8.1 KB
2025-11-12 06:55
半期報告書-第80期(2025/04/01-2026/03/31)
Japanese 196.8 KB
2025-06-24 08:14
臨時報告書
Japanese 23.0 KB
2025-06-23 06:58
内部統制報告書-第79期(2024/04/01-2025/03/31)
Japanese 22.6 KB
2025-06-23 06:57
確認書
Japanese 8.0 KB
2025-06-23 06:56
有価証券報告書-第79期(2024/04/01-2025/03/31)
Japanese 1.1 MB
2024-11-12 06:58
確認書
Japanese 8.0 KB
2024-11-12 06:56
半期報告書-第79期(2024/04/01-2025/03/31)
Japanese 191.1 KB
2024-06-27 06:53
内部統制報告書-第78期(2023/04/01-2024/03/31)
Japanese 21.9 KB
2024-06-27 06:52
確認書
Japanese 8.0 KB
2024-06-27 06:51
有価証券報告書-第78期(2023/04/01-2024/03/31)
Japanese 1.1 MB
2024-06-25 04:10
臨時報告書
Japanese 23.7 KB
2024-02-14 08:57
四半期報告書-第78期第3四半期(2023/10/01-2023/12/31)
Japanese 165.1 KB
2024-02-14 08:57
確認書
Japanese 8.0 KB
2023-11-14 05:06
確認書
Japanese 8.0 KB

Automate Your Workflow. Get a real-time feed of all SEIKAGAKU CORPORATION filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for SEIKAGAKU CORPORATION

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for SEIKAGAKU CORPORATION via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.